BACKGROUND: Dutch people born between 1925 and 1945 were ineligible for vaccination with the inactivated poliovirus vaccine (IPV) introduced in 1957 and may have escaped natural infection because of reduced poliovirus circulation. We examined whether people with low or undetectable antibody levels are susceptible to infection and whether memory immunity provides protection against virus excretion. METHODS: A total of 429 elderly participants were challenged with monovalent oral poliovirus vaccine (type 1 or 3) and followed for 8 weeks. Immune responses and virus excretion were compared for 4 groups, defined on the basis of seronegativity for poliovirus type 1 or 3, natural immunity, and IPV-induced immunity. RESULTS: On the basis of the rapidity of the antibody response and the absence of immunoglobulin M, we saw clear evidence of memory immune responses in 33% of the participants without detectable antibodies against poliovirus type 1 and in 5% of the participants without detectable antibodies against poliovirus type 3. Fecal virus-excretion patterns were not significantly different for seronegative participants, regardless of whether they showed evidence of memory immunity. CONCLUSIONS: Rapid antibody responses after challenge with oral polio vaccine provide evidence for poliovirus-specific memory immunity in seronegative elderly people. However, in contrast to preexisting immunity, memory immunity does not protect against virus excretion. These results have important implications for the poliomyelitis-eradication initiative, in particular for future immunization policies after eradication has been achieved.
BACKGROUND: Dutch people born between 1925 and 1945 were ineligible for vaccination with the inactivated poliovirus vaccine (IPV) introduced in 1957 and may have escaped natural infection because of reduced poliovirus circulation. We examined whether people with low or undetectable antibody levels are susceptible to infection and whether memory immunity provides protection against virus excretion. METHODS: A total of 429 elderly participants were challenged with monovalent oral poliovirus vaccine (type 1 or 3) and followed for 8 weeks. Immune responses and virus excretion were compared for 4 groups, defined on the basis of seronegativity for poliovirus type 1 or 3, natural immunity, and IPV-induced immunity. RESULTS: On the basis of the rapidity of the antibody response and the absence of immunoglobulin M, we saw clear evidence of memory immune responses in 33% of the participants without detectable antibodies against poliovirus type 1 and in 5% of the participants without detectable antibodies against poliovirus type 3. Fecal virus-excretion patterns were not significantly different for seronegative participants, regardless of whether they showed evidence of memory immunity. CONCLUSIONS: Rapid antibody responses after challenge with oral polio vaccine provide evidence for poliovirus-specific memory immunity in seronegative elderly people. However, in contrast to preexisting immunity, memory immunity does not protect against virus excretion. These results have important implications for the poliomyelitis-eradication initiative, in particular for future immunization policies after eradication has been achieved.
Authors: Kimberly M Thompson; Gregory S Wallace; Radboud J Duintjer Tebbens; Philip J Smith; Albert E Barskey; Mark A Pallansch; Kathleen M Gallagher; James P Alexander; Gregory L Armstrong; Stephen L Cochi; Steven G F Wassilak Journal: Public Health Rep Date: 2012 Jan-Feb Impact factor: 2.792
Authors: W J Lodder; A M Buisman; S A Rutjes; J C Heijne; P F Teunis; A M de Roda Husman Journal: Appl Environ Microbiol Date: 2012-03-23 Impact factor: 4.792
Authors: Bryan T Mayer; Joseph N S Eisenberg; Christopher J Henry; M Gabriela M Gomes; Edward L Ionides; James S Koopman Journal: Am J Epidemiol Date: 2013-04-16 Impact factor: 4.897
Authors: Cynthia J Snider; Khalequ Zaman; Concepcion F Estivariz; Mohammad Yunus; William C Weldon; Kathleen A Wannemuehler; M Steven Oberste; Mark A Pallansch; Steven Gf Wassilak; Tajul Islam A Bari; Abhijeet Anand Journal: Lancet Date: 2019-05-16 Impact factor: 79.321
Authors: Gabriel Trueba; Vishali Jeyaseelan; Lazaro Lopez; Bernardo A Mainou; Yiting Zhang; Alvaro Whittembury; Alfredo Jose Olmedo Valarezo; Gonzalo Baquero; Rosa Romero de Aguinaga; Lucia Jeannete Zurita Salinas; Maria Gabriela Santacruz Mancheno; Diana Elizabeth Medina Chacho; Emmanuelle Quentin; Ana Elena Chevez; Gloria Rey-Benito; Ondrej Mach Journal: Lancet Reg Health Am Date: 2022-07
Authors: Manuel Külshammer; Ute Winke; Monika Frank; Ursula Skali-Lami; Henrike Steudel; Gert Schilling; Jan Felix Drexler; Anna Maria Eis-Hübinger; Bertfried Matz Journal: Med Microbiol Immunol Date: 2012-06-13 Impact factor: 3.402
Authors: Ali Faisal Saleem; Ondrej Mach; Mohammad Tahir Yousafzai; Zaubina Kazi; Attaullah Baig; Muhammad Sajid; Vishali Jeyaseelan; Roland W Sutter; Anita K M Zaidi Journal: J Infect Dis Date: 2021-04-08 Impact factor: 5.226